View : 89 Download: 0

Full metadata record

DC Field Value Language
dc.contributor.author문영철-
dc.date.accessioned2019-12-03T16:30:19Z-
dc.date.available2019-12-03T16:30:19Z-
dc.date.issued2019-
dc.identifier.issn2152-2650-
dc.identifier.issn2152-2669-
dc.identifier.otherOAK-26054-
dc.identifier.urihttp://dspace.ewha.ac.kr/handle/2015.oak/252287-
dc.description.abstractDecitabine showed a survival benefit in the higher-risk group (Lower-Risk Prognostic Scoring System [LR-PSS] category 3) of the International Prognostic Scoring System (IPSS) lower-risk (IPSS low or intermediate-1) myelodysplastic syndrome patients who responded to decitabine. Therefore, classification using the LR-PSS category was helpful for this subgroup, indicating that decitabine treatment might alter the natural course of disease in these patients. Introduction: Decitabine has shown clinical benefits in patients with intermediate (INT)-2 or high-risk myelodysplastic syndrome (MDS), determined according to the International Prognostic Scoring System (IPSS), but the benefits have not been well demonstrated in patients with lower-risk (IPSS low or INT-1) disease. Recently, it was proposed that the prognosis for patients with IPSS lower-risk disease is heterogeneous, with a substantial proportion of these patients having poor survival. Patients and Methods: This study included patients with IPSS lower-risk MDS from the DRAMA (An Observational Study for Dacogen Long-Term Treatment in Patients With Myelodysplastic Syndrome; NCT01400633) and DIVA (A Study for Dacogen Treatment in Patients With Myelodysplastic Syndrome; NCT01041846) studies, which were prospective observational studies on the efficacy and safety of decitabine treatment in patients with MDS. Using the Lower-Risk Prognostic Scoring System [LR-PSS], we classified IPSS lower-risk MDS. Patients in each LR-PSS category were divided according to overall response (OR) to decitabine treatment, and survival outcomes were compared. Results: One hundred sixteen patients were enrolled: LR-PSS category 1 (n = 12; 10.3%), category 2 (n = 56; 48.3%), and category 3 (n = 48; 41.4%). Survival outcomes differed among the 3 categories (P = .046). The overall survival according to OR showed a significant difference in total patients (P = .008) and category 3 patients (P = .003). We analyzed predictive factors for OR, but no variable was found to significantly affect OR. Conclusion: Decitabine treatment showed a survival benefit in the higher-risk group of IPSS lower-risk MDS patients who responded to treatment, and classification using the LR-PSS category was helpful for this subgroup, indicating that decitabine treatment might alter the natural course of disease in these patients.-
dc.languageEnglish-
dc.publisherCIG MEDIA GROUP, LP-
dc.subjectDecitabine-
dc.subjectIPSS-
dc.subjectLower-Risk Prognostic Scoring System-
dc.subjectLR-PSS-
dc.subjectMyelodysplastic syndrome-
dc.titleClinical Outcomes of Decitabine Treatment for Patients With Lower-Risk Myelodysplastic Syndrome on the Basis of the International Prognostic Scoring System-
dc.typeArticle-
dc.relation.issue10-
dc.relation.volume19-
dc.relation.indexSCIE-
dc.relation.startpage656-
dc.relation.lastpage664-
dc.relation.journaltitleCLINICAL LYMPHOMA MYELOMA & LEUKEMIA-
dc.identifier.doi10.1016/j.clml.2019.06.003-
dc.identifier.wosidWOS:000493990400012-
dc.author.googleJung, Ki Sun-
dc.author.googleKim, Yoo-Jin-
dc.author.googleKim, Yeo-Kyeoung-
dc.author.googlePark, Sung Kyu-
dc.author.googleKim, Hoon Gu-
dc.author.googleKim, Soo Jeong-
dc.author.googlePark, Jinny-
dc.author.googleChoi, Chul Won-
dc.author.googleDo, Young Rok-
dc.author.googleKim, Inho-
dc.author.googlePark, Seonyang-
dc.author.googleMun, Yeung-Chul-
dc.author.googleJeong, Seong Hyun-
dc.author.googleKim, Min-Kyoung-
dc.author.googleYi, Hyeon Gyu-
dc.author.googleChang, Myung Hee-
dc.author.googleKim, Su Youn-
dc.author.googleLee, Je-Hwan-
dc.author.googleJang, Jun Ho-
dc.contributor.scopusid문영철(7003363716)-
dc.date.modifydate20191203135222-
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE